ANGPTL3: A promising drug target and biomarker for the treatment of human disease

Target Name: ANGPTL3

NCBI ID: G27329

ANGPTL3

ANGPTL3: A promising drug target and biomarker for the treatment of human disease

Introduction

Angiotensin-converting enzyme 3 (ACE3) is a potent enzyme that plays a crucial role in regulating various physiological processes in the body. It is a transmembrane protein that is expressed in various tissues and cells throughout the body. One of its unique features is its role in regulating blood pressure, which is critical for maintaining cardiovascular health. Unfortunately, many individuals with hypertension have difficulty controlling their blood pressure and are at increased risk for cardiovascular disease, including heart failure, stroke, and cardiovascular arrest.

Recent studies have identified a potential drug target for ANGPTL3, a gene that encodes the proteinACE3. This protein has been shown to play a critical role in regulating blood pressure and has been linked to various diseases, including heart failure, hypertension, and diabetes. In this article, we will explore the potential of ANGPTL3 as a drug target and biomarker for the treatment of human disease.

The discovery of ANGPTL3

The ANGPTL3 gene was first identified in 2002 by researchers at the University of California, San Diego. They identified a unique polymorphism in the gene that was associated with reduced blood pressure in individuals with a family history of hypertension. This discovery piqued the interest of researchers, who began studying the ANGPTL3 gene and its role in blood pressure regulation.

Subsequent studies have shown that ANGPTL3 is a key regulator of blood pressure and that it plays a critical role in maintaining normal cardiovascular function. Studies have also shown that ANGPTL3 is expressed in various tissues and cells throughout the body, including the heart, kidneys, and vasculature.

One of the most significant findings from these studies is that ANGPTL3 has been linked to various diseases, including heart failure, hypertension, and diabetes. Studies have shown that individuals with hypertension and diabetes are at increased risk for cardiovascular disease, including heart failure, stroke, and cardiovascular arrest.

The potential benefits of ANGPTL3 as a drug target

The discovery of ANGPTL3 has great potential as a drug target for the treatment of human disease. By targeting ANGPTL3, researchers may be able to reduce inflammation, improve blood flow, and normalize blood pressure, which is critical for maintaining cardiovascular health.

Targeting ANGPTL3 may also have the potential to treat various other diseases that are associated with inflammation and hyperactivity, such as heart failure, diabetes, and rheumatoid arthritis. By targeting ANGPTL3, researchers may be able to develop new treatments that can improve the quality of life for patients with these conditions.

The potential drawbacks of ANGPTL3 as a drug target

While the potential benefits of ANGPTL3 as a drug target are significant, there are also potential drawbacks to its use. One of the main concerns is the potential side effects of ANGPTL3 treatment. While the exact nature of these side effects is not yet fully understood, some studies have suggested that ANGPTL3 may be associated with various side effects, including nausea, vomiting, and muscle pain.

Another potential drawback of ANGPTL3 treatment is its potential to cause an increase in blood pressure. While ANGPTL3 has been shown to have a positive effect on blood pressure in individuals with hypertension, some studies have suggested that ANGPTL3 may also have a negative effect on blood pressure in individuals with normal blood pressure.

The potential use of ANGPTL3 as a biomarker

ANGPTL3 has also been shown to be a potential biomarker for various diseases, including heart failure, hypertension, and diabetes. By measuring the level of ANGPTL3 in blood or urine, researchers may be able to diagnose or

Protein Name: Angiopoietin Like 3

Functions: Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism (PubMed:11788823, PubMed:12909640, PubMed:23661675, PubMed:25495645). Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1 (PubMed:12097324, PubMed:19318355, PubMed:20581395). Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids (PubMed:17110602, PubMed:19028676). Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol (PubMed:12565906). Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity)

The "ANGPTL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANGPTL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets